Ís
lenska
Search
My pages
Main menu
Close
Medicinal products
Development
Medical Devices
Regulated entities
Pricing and Reimbursement
Published Material
IMA
Medicinal products
About Medicinal products
Importation by Individuals of Medicinal Products for Personal Use
Marketing Authorisations
Conditions for Marketing
Electronic Applications
Package labelling and leaflets
Other Registrations/Authorisations
RMS Requests
Text Processing
Withdrawals
Zero Day Procedure
Pharmacovigilance
Report an Adverse Drug Reaction
Quality Standards
Reported Medicine Shortage – Overview
Safety Features of Medicinal Products
Development
About Development
Clinical Trials
Application for a Clinical Trial
Clinical Trials Information System (CTIS)
Substantial Amendments
Notifications and Reports
SUSAR Reporting
Approvals for Clinical Trial Applications
CTFG / VHP
Scientific Advice
Medical Devices
About Medical Devices
Instructions for use
Use and vigilance of Medical Devices
Registration of distributors
CE Marking
Incident Report for Medical Devices
Regulated entities
About Regulated entities
Manufacturers
Medical Centers
Narcotic Drugs and Other Controlled Substances
Controlled Substances
Narcotics
Other Regulated Entities
Pharmacies
Pharmacy License
Wholesalers and Distributors
Licenses for Import and Wholesale Distribution of Medicinal Products
Pricing and Reimbursement
About Pricing and reimbursement
Icelandic Medicine Price Catalogue
The Exchange Rate of the Icelandic Price Catalogue
Published Material
About Published Material
Annual Reports
FAQ
Forms
Guidelines
Lists
News
IMA
About IMA
Roles and Organization
Strategy
Employees
Fees
Laws and Regulations
Type your search and press enter
Search here!
Type what you want to find
Greinasafn
December 17, 2021
08. What is the meaning of the red warning triangle?
December 17, 2021
07. How long is there an obligation to create and submit PSURs or RMPs after a marketing authorisation was withdrawn?
December 17, 2021
06. How long is there an obligation to continue collection and submission of spontaneous ADR reports after a marketing authorisation of the suspect product was withdrawn?
December 17, 2021
05. Are Marketing Authorisation Holders required to have a Local Contact Person for Pharmacovigilance in Iceland?
December 17, 2021
04. Are Marketing Authorisation Holders required to have a Qualified Person for PharmacoVigilance (QPPV) residing in Iceland?
December 17, 2021
03. Does IMA require literature reports for Icelandic cases? Should a copy of the literature article be attached?
December 17, 2021
02. Is there a list of local literature that the Marketing Authorisation Holders should monitor?
December 17, 2021
01. What happens to ICSRs received by IMA from healthcare professionals and the public?